IFNG and B-cell chronic lymphocytic leukemia: Conversely, even though IFNγ is currently used as a clinical target for treatment of malignancies, enhanced IFNγ production by ILC1s is not associated with a better immune response but shows an immunosuppressive effect in the presence of IL-12-producing chronic lymphocytic leukemia (CLL) cells (117, 124).